Advances in kidney disease and health最新文献

筛选
英文 中文
Rethinking Fluid Balance: The Shift Toward Deresuscitation in Critical Care 重新思考体液平衡:向危重监护去复苏的转变
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.07.003
Ashley La, Mohammad S. Sheikh, Jay L. Koyner
{"title":"Rethinking Fluid Balance: The Shift Toward Deresuscitation in Critical Care","authors":"Ashley La, Mohammad S. Sheikh, Jay L. Koyner","doi":"10.1053/j.akdh.2026.07.003","DOIUrl":"10.1053/j.akdh.2026.07.003","url":null,"abstract":"<div><div>Intravenous fluid therapy is central to resuscitating critically ill patients, yet accumulating evidence shows that excessive fluid administration and positive fluid balance contribute directly to respiratory failure, acute kidney injury, prolonged mechanical ventilation, and mortality. Modern fluid stewardship reframes intravenous fluids as pharmacologic agents with dose-dependent toxicity and emphasizes the ROSE (Resuscitation, Optimization, Stabilization, and Evacuation) model. Observational studies consistently link fluid overload (often defined as fluid balance >5% baseline weight) to worse outcomes, and early or protocolized deresuscitation (removal of accumulated fluid once perfusion goals have been achieved) through diuretics or ultrafiltration can reliably achieve negative fluid balance and improve pulmonary parameters without increasing acute kidney injury. Randomized trials of restrictive strategies demonstrate improved ventilator-free days and shortened length of stay but no mortality benefit, underscoring the need for individualized, physiology-guided approaches. Evidence for active deresuscitation remains mixed. Diuretic-based protocols can lower mortality and reduce renal replacement therapy use in select populations, while ultrafiltration studies highlight the importance of avoiding both insufficient (<1 mL/kg/h) and excessive (>1.75 mL/hg/h) fluid removal rates. Knowledge gaps persist around optimal timing, patient selection, hemodynamic monitoring, and fluid removal targets. Ongoing trials aim to refine protocolized resuscitation and better define strategies to safely restore euvolemia, mitigate organ dysfunction, and improve outcomes in critical illness.</div></div><div>Intravenous fluid therapy is central to resuscitating critically ill patients, yet accumulating evidence shows that excessive fluid administration and positive fluid balance contribute directly to respiratory failure, acute kidney injury, prolonged mechanical ventilation, and mortality. Modern fluid stewardship reframes intravenous fluids as pharmacologic agents with dose-dependent toxicity and emphasizes the ROSE (Resuscitation, Optimization, Stabilization, and Evacuation) model. Observational studies consistently link fluid overload (often defined as fluid balance >5% baseline weight) to worse outcomes, and early or protocolized deresuscitation (removal of accumulated fluid once perfusion goals have been achieved) through diuretics or ultrafiltration can reliably achieve negative fluid balance and improve pulmonary parameters without increasing acute kidney injury. Randomized trials of restrictive strategies demonstrate improved ventilator-free days and shortened length of stay but no mortality benefit, underscoring the need for individualized, physiology-guided approaches. Evidence for active deresuscitation remains mixed. Diuretic-based protocols can lower mortality and reduce renal replacement therapy use in select populations, while u","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 234-242"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Injury After Hematopoietic Stem CellTransplantation 造血干细胞移植后急性肾损伤
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.08.002
Ahmad Bilal Malik
{"title":"Acute Kidney Injury After Hematopoietic Stem CellTransplantation","authors":"Ahmad Bilal Malik","doi":"10.1053/j.akdh.2026.08.002","DOIUrl":"10.1053/j.akdh.2026.08.002","url":null,"abstract":"<div><div>Hematopoietic stem cell transplantation is a curative intervention for various hematologic malignancies. However, it is associated with an exceptionally high rate of acute kidney injury with a cumulative incidence of 55%. The risk is highest for unmatched allogeneic transplantation involving myeloablative conditioning regimens. The need for kidney replacement therapy can approach 21% especially in critically ill recipients with unacceptably high all-cause and nonrelapse mortality. Various factors predispose to kidney injury extending from the toxicity of conditioning regimen to a myriad of complications spanning up to 100 days post-transplantation. An understanding of this timeline as well as the pathophysiology of the various processes facilitates early recognition and prompt management. Advances in therapeutics bring optimism in improving outcomes and minimizing progressive tissue injury.</div></div><div>Hematopoietic stem cell transplantation is a curative intervention for various hematologic malignancies. However, it is associated with an exceptionally high rate of acute kidney injury with a cumulative incidence of 55%. The risk is highest for unmatched allogeneic transplantation involving myeloablative conditioning regimens. The need for kidney replacement therapy can approach 21% especially in critically ill recipients with unacceptably high all-cause and nonrelapse mortality. Various factors predispose to kidney injury extending from the toxicity of conditioning regimen to a myriad of complications spanning up to 100 days post-transplantation. An understanding of this timeline as well as the pathophysiology of the various processes facilitates early recognition and prompt management. Advances in therapeutics bring optimism in improving outcomes and minimizing progressive tissue injury.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 256-268"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Intersection of Venous Congestion and Arterial Underfilling in Cardiorenal Syndromes 心肾综合征中静脉充血与动脉充血不足的交点。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-07-29 DOI: 10.1053/j.akdh.2026.06.007
Jeffrey M. Turner, Laura Aponte Becerra, Christopher El Mouhayyar
{"title":"The Intersection of Venous Congestion and Arterial Underfilling in Cardiorenal Syndromes","authors":"Jeffrey M. Turner,&nbsp;Laura Aponte Becerra,&nbsp;Christopher El Mouhayyar","doi":"10.1053/j.akdh.2026.06.007","DOIUrl":"10.1053/j.akdh.2026.06.007","url":null,"abstract":"<div><div>The heart and kidneys are connected in both health and disease. Coordinated dysfunction of these organ systems is a result of complex interactions related to vascular and biochemical maladaptations. The historical perspective that kidney dysfunction in heart failure is overwhelmingly a product of reduced cardiac forward flow and arterial underfilling has been challenged by mounting evidence. Efforts in 2004 to introduce the term cardiorenal syndrome were based on observations that increased circulatory volume, specifically venous congestion, play a key role in kidney dysfunction. Contemporary studies done after 2004, as well as revisiting historical renal physiology experiments in a new light, have illuminated some of the pathophysiology of how venous congestion in decompensated heart failure causes the “congested kidney.” Cardiorenal syndrome, specifically type 1 occurring in the setting of acute heart failure, in part is defined by the fact that renal venous hypertension drives kidney dysfunction. To illuminate this point further, we compare and contrast the importance of arterial underfilling in cardiogenic shock vs cardiorenal syndrome.</div></div><div>The heart and kidneys are connected in both health and disease. Coordinated dysfunction of these organ systems is a result of complex interactions related to vascular and biochemical maladaptations. The historical perspective that kidney dysfunction in heart failure is overwhelmingly a product of reduced cardiac forward flow and arterial underfilling has been challenged by mounting evidence. Efforts in 2004 to introduce the term cardiorenal syndrome were based on observations that increased circulatory volume, specifically venous congestion, play a key role in kidney dysfunction. Contemporary studies done after 2004, as well as revisiting historical renal physiology experiments in a new light, have illuminated some of the pathophysiology of how venous congestion in decompensated heart failure causes the “congested kidney.” Cardiorenal syndrome, specifically type 1 occurring in the setting of acute heart failure, in part is defined by the fact that renal venous hypertension drives kidney dysfunction. To illuminate this point further, we compare and contrast the importance of arterial underfilling in cardiogenic shock vs cardiorenal syndrome.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 243-247"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactate in Context: Physiology and Clinical Judgment 乳酸:生理学和临床判断
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.07.004
Chelsea Takamatsu, Erin Ryan, Ralph Mohty
{"title":"Lactate in Context: Physiology and Clinical Judgment","authors":"Chelsea Takamatsu,&nbsp;Erin Ryan,&nbsp;Ralph Mohty","doi":"10.1053/j.akdh.2026.07.004","DOIUrl":"10.1053/j.akdh.2026.07.004","url":null,"abstract":"<div><div>Lactate is among the most frequently measured biomarkers in clinical care, yet its pathophysiologic interpretation remains frequently misunderstood. Historically regarded as a byproduct of anaerobic metabolism and a direct cause of acidosis, lactate is now recognized as a central intermediary in numerous physiologic processes. This review emphasizes a physiologic framework of lactate kinetics, highlighting the dynamic balance between production and clearance in the interpretation of hyperlactatemia. Clinically, lactate is best understood as a contextual biomarker reflecting both hypoxic and nonhypoxic processes, including catecholamine or malignancy-driven glycolysis, mitochondrial dysfunction, and impaired clearance. At the bedside, an elevated lactate should prompt a structured assessment of hemodynamic phenotype, incorporating both macrocirculatory and microcirculatory considerations. Interventions aimed solely at reducing lactate or its associated acidosis have not consistently demonstrated improved outcomes, whereas therapies directed at the underlying disease process are of critical importance. Ultimately, lactate should not be viewed as a therapeutic target in isolation but as a signal to guide physiology-driven clinical judgment.</div></div><div>Lactate is among the most frequently measured biomarkers in clinical care, yet its pathophysiologic interpretation remains frequently misunderstood. Historically regarded as a byproduct of anaerobic metabolism and a direct cause of acidosis, lactate is now recognized as a central intermediary in numerous physiologic processes. This review emphasizes a physiologic framework of lactate kinetics, highlighting the dynamic balance between production and clearance in the interpretation of hyperlactatemia. Clinically, lactate is best understood as a contextual biomarker reflecting both hypoxic and nonhypoxic processes, including catecholamine or malignancy-driven glycolysis, mitochondrial dysfunction, and impaired clearance. At the bedside, an elevated lactate should prompt a structured assessment of hemodynamic phenotype, incorporating both macrocirculatory and microcirculatory considerations. Interventions aimed solely at reducing lactate or its associated acidosis have not consistently demonstrated improved outcomes, whereas therapies directed at the underlying disease process are of critical importance. Ultimately, lactate should not be viewed as a therapeutic target in isolation but as a signal to guide physiology-driven clinical judgment.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 216-223"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and Therapeutic Challenges in CKD Patients With Tumor Lysis Syndrome and Rhabdomyolysis CKD合并肿瘤溶解综合征和横纹肌溶解患者的诊断和治疗挑战
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.08.005
Dharni Patel, Priya Deshpande
{"title":"Diagnostic and Therapeutic Challenges in CKD Patients With Tumor Lysis Syndrome and Rhabdomyolysis","authors":"Dharni Patel,&nbsp;Priya Deshpande","doi":"10.1053/j.akdh.2026.08.005","DOIUrl":"10.1053/j.akdh.2026.08.005","url":null,"abstract":"<div><div>Tumor lysis syndrome (TLS) and rhabdomyolysis are pathologically distinct disease processes; however, both can result in severe acute kidney injury (AKI) due to tubular injury—uric acid and calcium phosphate nephropathy in TLS and pigment nephropathy in rhabdomyolysis. Each condition requires a high degree of clinical suspicion for timely diagnosis and carries a significant risk of life-threatening electrolyte disturbances, particularly in the setting of AKI. Although strategies to prevent AKI in these conditions have important nuances, the mainstay of management remains aggressive isotonic intravenous fluid administration, with the addition of rasburicase in TLS. Nevertheless, clinicians face substantial challenges in managing these disorders because of their clinical complexity and the limited availability of high-quality evidence. This manuscript reviews common pitfalls in the management of TLS and rhabdomyolysis, highlighting the best practices currently employed in clinical care.</div></div><div>Tumor lysis syndrome (TLS) and rhabdomyolysis are pathologically distinct disease processes; however, both can result in severe acute kidney injury (AKI) due to tubular injury—uric acid and calcium phosphate nephropathy in TLS and pigment nephropathy in rhabdomyolysis. Each condition requires a high degree of clinical suspicion for timely diagnosis and carries a significant risk of life-threatening electrolyte disturbances, particularly in the setting of AKI. Although strategies to prevent AKI in these conditions have important nuances, the mainstay of management remains aggressive isotonic intravenous fluid administration, with the addition of rasburicase in TLS. Nevertheless, clinicians face substantial challenges in managing these disorders because of their clinical complexity and the limited availability of high-quality evidence. This manuscript reviews common pitfalls in the management of TLS and rhabdomyolysis, highlighting the best practices currently employed in clinical care.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 224-233"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Customizing Treatment for Acute Kidney Injury in Distinct Populations 不同人群急性肾损伤的个性化治疗。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-10-14 DOI: 10.1053/j.akdh.2026.08.006
Sarah F. Sanghavi, Ladan Golestaneh
{"title":"Customizing Treatment for Acute Kidney Injury in Distinct Populations","authors":"Sarah F. Sanghavi,&nbsp;Ladan Golestaneh","doi":"10.1053/j.akdh.2026.08.006","DOIUrl":"10.1053/j.akdh.2026.08.006","url":null,"abstract":"","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 205-206"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149186574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of Acute Kidney Injury During Pregnancy 妊娠期急性肾损伤的诊断。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-09-23 DOI: 10.1053/j.akdh.2026.06.004
Aditi Singh, Sumeska Thavarajah, Nityasree Srialluri
{"title":"Diagnosis of Acute Kidney Injury During Pregnancy","authors":"Aditi Singh,&nbsp;Sumeska Thavarajah,&nbsp;Nityasree Srialluri","doi":"10.1053/j.akdh.2026.06.004","DOIUrl":"10.1053/j.akdh.2026.06.004","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Pregnancy-related acute kidney injury (PrAKI) is a serious complication causing substantial maternal and fetal morbidity and mortality with long-term sequelae including chronic kidney disease (CKD) and cardiovascular disease. PrAKI affects individuals across high- and low-resource settings, though epidemiology, etiologies, and outcomes differ substantially by context. In low-resource settings, PrAKI remains a leading cause of maternal mortality, precipitated by septic abortion, hemorrhage, and hypertensive disorders compounded by limited access to renal replacement therapy. In high-income countries, PrAKI incidence of is rising due to increasing maternal age, cardiometabolic comorbidities, and hypertensive disorders of pregnancy. PrAKI ranges from transient, reversible dysfunction to severe injury necessitating dialysis, with adverse at each stage. Diagnosis is uniquely challenging because physiological adaptations of pregnancy lower serum creatinine, rendering conventional thresholds less reliable. Current AKI definitions and kidney function estimating equations remain unvalidated in pregnant populations and pre-existing CKD may mask superimposed injury when baseline creatinine values are unknown. Management requires a multidisciplinary approach tailored to gestational age and underlying etiology. In this review, we focus on diagnostic strategies for PrAKI—including gestational age–adjusted creatinine trajectories, proteinuria assessment, and emerging kidney and placental biomarkers—alongside clinical management principles, and current gaps in knowledge.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Pregnancy-related acute kidney injury (PrAKI) is a serious complication causing substantial maternal and fetal morbidity and mortality with long-term sequelae including chronic kidney disease (CKD) and cardiovascular disease. PrAKI affects individuals across high- and low-resource settings, though epidemiology, etiologies, and outcomes differ substantially by context. In low-resource settings, PrAKI remains a leading cause of maternal mortality, precipitated by septic abortion, hemorrhage, and hypertensive disorders compounded by limited access to renal replacement therapy. In high-income countries, PrAKI incidence of is rising due to increasing maternal age, cardiometabolic comorbidities, and hypertensive disorders of pregnancy. PrAKI ranges from transient, reversible dysfunction to severe injury necessitating dialysis, with adverse at each stage. Diagnosis is uniquely challenging because physiological adaptations of pregnancy lower serum creatinine, rendering conventional thresholds less reliable. Current AKI definitions and kidney function estimating equations remain unvalidated in pregnant populations and pre-existing CKD may mask superimposed injury when baseline creatinine values are unknown. Management requires a multidisciplinary approach tailored to gestational age and underlying etiology. In this review, we focus on diagnostic strategies for PrAKI—including ge","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 269-277"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperammonemia Physiology and Management: A Nephrology-Centered Review 高氨血症的生理和管理:以肾脏病为中心的综述。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-07-02 DOI: 10.1053/j.akdh.2026.06.001
Patrick Hofmann, Danielle L. Saly
{"title":"Hyperammonemia Physiology and Management: A Nephrology-Centered Review","authors":"Patrick Hofmann,&nbsp;Danielle L. Saly","doi":"10.1053/j.akdh.2026.06.001","DOIUrl":"10.1053/j.akdh.2026.06.001","url":null,"abstract":"<div><div>Hyperammonemia is a rare but life-threatening disorder that arises from hepatic and diverse nonhepatic etiologies and demands prompt physiologic evaluation and intervention to prevent neurologic injury. This review highlights the physiological roles of the intestine, liver, skeletal muscle, brain, and kidneys in ammonia homeostasis, with emphasis on acid-base and potassium regulation. We summarize major causes of hyperammonemia, diagnostic strategies, and nondialytic therapies, review principles guiding kidney replacement therapy selection and dosing, and identify key uncertainties that warrant future study in adult populations.</div></div><div>Hyperammonemia is a rare but life-threatening disorder that arises from hepatic and diverse nonhepatic etiologies and demands prompt physiologic evaluation and intervention to prevent neurologic injury. This review highlights the physiological roles of the intestine, liver, skeletal muscle, brain, and kidneys in ammonia homeostasis, with emphasis on acid-base and potassium regulation. We summarize major causes of hyperammonemia, diagnostic strategies, and nondialytic therapies, review principles guiding kidney replacement therapy selection and dosing, and identify key uncertainties that warrant future study in adult populations.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 207-215"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Acute Kidney Injury in Severe Acute BrainInjury 重型急性脑损伤并发急性肾损伤的处理
IF 3.1
Advances in kidney disease and health Pub Date : 2026-05-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.08.001
Neev Patel, Hannah L. Kirsch, Pedram Fatehi
{"title":"Management of Acute Kidney Injury in Severe Acute BrainInjury","authors":"Neev Patel,&nbsp;Hannah L. Kirsch,&nbsp;Pedram Fatehi","doi":"10.1053/j.akdh.2026.08.001","DOIUrl":"10.1053/j.akdh.2026.08.001","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Acute kidney injury (AKI) complicates 10-25% of neurocritical care admissions and is associated with approximately doubled mortality in patients with traumatic brain injury, acute ischemic stroke, intracerebral hemorrhage, and aneurysmal subarachnoid hemorrhage. The brain and kidney share vulnerability to hemodynamic insults and interact bidirectionally: severe acute brain injury triggers sympathetic activation, systemic inflammation, and iatrogenic exposures that compromise renal function, whereas AKI promotes uremic neurotoxicity and fluid and electrolyte disturbances that worsen cerebral edema. Among patients who do not develop AKI, augmented renal clearance affects up to 74% of neurocritical care patients and causes subtherapeutic drug concentrations. Management depends on the specific type of brain injury and requires balancing cerebral perfusion pressure targets, volume status, osmotherapy, and solute clearance. When kidney replacement therapy is indicated, continuous modalities are generally preferred to minimize osmotic shifts and intracranial pressure fluctuations. Maintaining therapeutic hypernatremia during continuous renal replacement therapy requires concurrent hypertonic saline infusion calculated by mass balance principles. For patients with established AKI requiring osmotherapy, hypertonic saline is often favored over mannitol given comparable efficacy without risk of osmotic nephrosis. Evidence specific to this population remains limited, and current practice relies on physiologic principles and close collaboration between nephrology and neurocritical care teams.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Acute kidney injury (AKI) complicates 10-25% of neurocritical care admissions and is associated with approximately doubled mortality in patients with traumatic brain injury, acute ischemic stroke, intracerebral hemorrhage, and aneurysmal subarachnoid hemorrhage. The brain and kidney share vulnerability to hemodynamic insults and interact bidirectionally: severe acute brain injury triggers sympathetic activation, systemic inflammation, and iatrogenic exposures that compromise renal function, whereas AKI promotes uremic neurotoxicity and fluid and electrolyte disturbances that worsen cerebral edema. Among patients who do not develop AKI, augmented renal clearance affects up to 74% of neurocritical care patients and causes subtherapeutic drug concentrations. Management depends on the specific type of brain injury and requires balancing cerebral perfusion pressure targets, volume status, osmotherapy, and solute clearance. When kidney replacement therapy is indicated, continuous modalities are generally preferred to minimize osmotic shifts and intracranial pressure fluctuations. Maintaining therapeutic hypernatremia during continuous renal replacement therapy requires concurrent hypertonic saline infusion calculated by mass balance principles. For patients with established AKI requiring osmotherapy, hypertonic saline is often favored over mannitol gi","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 3","pages":"Pages 248-255"},"PeriodicalIF":3.1,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Aldosteronism and the Kidneys 原发性醛固酮增多症与肾脏。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-03-01 Epub Date: 2026-07-02 DOI: 10.1053/j.akdh.2026.04.001
Emily L. Simms, Gregory L. Hundemer
{"title":"Primary Aldosteronism and the Kidneys","authors":"Emily L. Simms,&nbsp;Gregory L. Hundemer","doi":"10.1053/j.akdh.2026.04.001","DOIUrl":"10.1053/j.akdh.2026.04.001","url":null,"abstract":"<div><div>Primary aldosteronism (PA) is the most common and modifiable form of secondary hypertension, being responsible for 5-10% of all cases of hypertension and over 20% of cases of resistant hypertension. PA is characterized by autonomous aldosterone secretion from 1 or both adrenal glands, independent of regulation by renin and angiotensin II. Although the adverse cardiovascular consequences garner the majority of attention in regard to its clinical impact, PA leads to important detrimental effects on kidney health also. This includes early glomerular hyperfiltration followed by albuminuria, steeper longitudinal estimated glomerular filtration rate decline, and a higher risk for CKD. Importantly, early diagnosis and initiation of targeted therapies, namely surgical adrenalectomy and mineralocorticoid receptor antagonist medications, effectively mitigate these kidney disease risks. Although these aldosterone-targeted therapies provide long-term kidney protection, they often “unmask” previously unrecognized CKD due to reversal of the longstanding glomerular hyperfiltration inherent to the pathophysiology of PA. Herein, a teaching case is discussed which highlights the diagnostic and treatment approaches to PA along with commonly encountered kidney manifestations which arise from PA and its treatments.</div></div><div>Primary aldosteronism (PA) is the most common and modifiable form of secondary hypertension, being responsible for 5-10% of all cases of hypertension and over 20% of cases of resistant hypertension. PA is characterized by autonomous aldosterone secretion from 1 or both adrenal glands, independent of regulation by renin and angiotensin II. Although the adverse cardiovascular consequences garner the majority of attention in regard to its clinical impact, PA leads to important detrimental effects on kidney health also. This includes early glomerular hyperfiltration followed by albuminuria, steeper longitudinal estimated glomerular filtration rate decline, and a higher risk for CKD. Importantly, early diagnosis and initiation of targeted therapies, namely surgical adrenalectomy and mineralocorticoid receptor antagonist medications, effectively mitigate these kidney disease risks. Although these aldosterone-targeted therapies provide long-term kidney protection, they often “unmask” previously unrecognized CKD due to reversal of the longstanding glomerular hyperfiltration inherent to the pathophysiology of PA. Herein, a teaching case is discussed which highlights the diagnostic and treatment approaches to PA along with commonly encountered kidney manifestations which arise from PA and its treatments.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 2","pages":"Pages 135-142"},"PeriodicalIF":3.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书